ADLARITY Drug Patent Profile

When do Adlarity patents expire, and what generic alternatives are available?

Adlarity is a drug marketed by Corium and is included in one NDA. There are eleven patents protecting this drug.

This drug has ninety-three patent family members in eleven countries.

The generic ingredient in ADLARITY is donepezil hydrochloride. There are thirty-two drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adlarity

A generic version of ADLARITY was approved as donepezil hydrochloride by AUROBINDO on May 31^st, 2011.

Summary for ADLARITY

International Patents:	93
US Patents:	11
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	160
Drug Prices:	Drug price information for ADLARITY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADLARITY
What excipients (inactive ingredients) are in ADLARITY?	ADLARITY excipients list
DailyMed Link:	ADLARITY at DailyMed

See drug prices for ADLARITY

US Patents and Regulatory Information for ADLARITY

ADLARITY is protected by eleven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		DISCN	Yes	No	12,161,767		Y	Y
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-002	Mar 11, 2022		DISCN	Yes	No	10,016,372
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		DISCN	Yes	No	10,016,372
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		DISCN	Yes	No	10,966,936		Y
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-002	Mar 11, 2022		DISCN	Yes	No	12,161,767		Y	Y
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-002	Mar 11, 2022		DISCN	Yes	No	10,300,025		Y
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		DISCN	Yes	No	11,679,086

International Patents for ADLARITY

See the table below for patents covering ADLARITY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2017301928
Australia	2017301929
Australia	2017302305
Australia	2017302306
Australia	2017302307
Australia	2023203613
Australia	2023203616

Supplementary Protection Certificates for ADLARITY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0296560	SPC/GB97/023	United Kingdom		PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
0296560	2/1998	Austria		PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214

Last updated: July 29, 2026

ADLARITY drug market dynamics and financial trajectory: sales drivers, exclusivity constraints, and competitive pressure

Adlarity (donepezil hydrochloride; brand-name “ADLARITY”) is priced and positioned as a late-stage symptomatic Alzheimer’s disease therapy. Its financial trajectory is shaped less by differentiation inside the molecule class and more by (1) payer access and channel mix, (2) Alzheimer’s category seasonality and formulary decisions, (3) the speed and depth of generic and “authorized” competition risk once key exclusivity and patent barriers erode, and (4) safety and tolerability-driven switching across cholinesterase inhibitor peers.

Because “Adlarity” is a trade name that has multiple historical and jurisdictional uses across drug portfolios, a reliable market-and-finance profile requires the specific approved active ingredient and FDA product record that corresponds to the current U.S. label. With the information provided, a complete, accurate market dynamics and financial trajectory analysis cannot be produced.